Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
AORT: A holder filed a Form 144 notice to sell 6,393 shares of common stock through Fidelity Brokerage Services, with an aggregate market value $285,575.31. The filing lists an approximate sale date of 11/14/2025 on the NYSE. Shares outstanding were 47,374,939.
The shares to be sold were acquired on 11/14/2025 via an option originally granted on 03/05/2019, with payment noted as cash. The filing also reports past 3‑month sales by John E. Davis: 3,373 shares on 11/10/2025 for $150,499.55 and 6,563 shares on 11/13/2025 for $300,968.02.
AORT received a Form 144 notice covering a proposed sale of 3,482 common shares. The filing lists an aggregate market value of $159,678.60, with an approximate sale date of 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired via restricted stock vesting on 11/10/2025 and 11/11/2025 in two equal tranches of 1,741 shares each, characterized as compensation. The filing also reports that Amy D. Horton sold 1,789 shares on 11/11/2025 for $79,823.21 in gross proceeds. Shares outstanding are listed as 47,374,939.
AORT filed a Form 144 notice for a proposed sale under Rule 144 by security holder Jean F. Holloway. The filing lists 5,761 shares of common stock to be sold, with an aggregate market value of $264,189.66, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025. Shares outstanding are shown as 47,374,939.
The shares to be sold were acquired via restricted stock vesting: 2,880 shares on 11/10/2025 and 2,881 shares on 11/11/2025, labeled as compensation. In the past three months, the filer reported sales of 10,000 shares on 08/25/2025 for $443,700.00, 2,960 shares on 11/10/2025 for $132,071.94, and 10,000 shares on 11/11/2025 for $461,800.00.
AORT disclosed a Form 144 notice for a proposed sale of 34,210 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $1,568,812.44. The filing lists an approximate sale date of 11/13/2025 on the NYSE.
The shares derive from recent restricted stock vesting: 17,105 shares on 11/10/2025 and 17,105 shares on 11/11/2025, each marked as Compensation. A recent activity section shows sales in the last three months by James Mackin of 12,500 shares on 08/15/2025 for $528,991.00 and 17,580 shares on 11/11/2025 for $784,400.26. Shares outstanding were 47,374,939 at the time referenced in the filing.
AORT filed a Form 144 for a proposed sale of up to 4,993 common shares, with an aggregate market value of $228,970.50. The approximate sale date is 11/13/2025, through Fidelity Brokerage Services LLC, on the NYSE.
The shares were acquired via restricted stock vesting as compensation: 2,496 shares on 11/10/2025 and 2,497 shares on 11/11/2025. In the past three months, the seller reported sales of 18,200 shares on 08/27/2025 for $801,211.32 and 2,566 shares on 11/11/2025 for $114,492.10. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being offered.
John E. Davis filed a Form 144 notice to sell up to 6,563 shares of common stock, with an aggregate market value of
The securities were acquired via restricted stock vesting from the issuer on
Artivion (AORT): Schedule 13G/A Amendment No. 6—Macquarie Group Limited and affiliates reported beneficial ownership of 2,483,842 Artivion common shares, representing 5.26% of the class as of September 30, 2025. Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust report sole voting and dispositive power over 2,483,842 shares. The certification states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) insider activity: The company’s SVP and General Counsel reported multiple transactions. On 11/10/2025, 2,960 shares of common stock were sold at
The option exercised was originally granted with vesting at 33 1/3% per year beginning on 11/08/2023 and had an expiration date of 11/08/2029.
Artivion (AORT)
On 11/10/2025, 17,580 shares of common stock were sold at $44.619 in a sell-to-cover tied to RSU vesting to satisfy tax withholding; the filing states this was not a discretionary trade.
After the transaction, he directly beneficially owned 835,203 shares.
Artivion, Inc. (AORT) reported an insider transaction. Chief Commercial Officer John E. Davis disclosed the sale of 3,373 shares of common stock on 11/10/2025 at $44.619 per share.
The filing states the shares were sold upon RSU vesting to cover tax withholding obligations via a sell-to-cover and “does not represent a discretionary transaction.” Following the transaction, Davis directly beneficially owned 205,405 shares.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
